Inhibiting IgG in Hemolytic Disease of the Fetus

N Engl J Med. 2024 Aug 8;391(6):563-567. doi: 10.1056/NEJMe2401020.

Authors

Emeline Maisonneuve¹, Alice Panchaud¹, David Baud¹

Affiliation

¹ From the Materno-fetal and Obstetrics Research Unit, Department "Femme-Mère-Enfant" (E.M., D.B.), and the Service of Pharmacy (A.P.), Lausanne University Hospital and University of Lausanne, Lausanne, and the Institute of Primary Health Care (E.M., A.P.) and the Graduate School for Health Sciences (E.M.), University of Bern, Bern - all in Switzerland.

PMID: 39115067
DOI: 10.1056/NEJMe2401020

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects
Blood Transfusion, Intrauterine
Clinical Trials, Phase II as Topic
Erythroblastosis, Fetal* / blood
Erythroblastosis, Fetal* / diagnosis
Erythroblastosis, Fetal* / immunology
Erythroblastosis, Fetal* / therapy
Female
Histocompatibility Antigens Class I / blood
Histocompatibility Antigens Class I / immunology
Humans
Immunoglobulin G* / blood
Immunoglobulin G* / immunology
Immunoglobulin G* / metabolism
Immunoglobulins, Intravenous / administration & dosage
Isoantigens / blood
Isoantigens / immunology
Isoantigens / metabolism
Plasma Exchange
Pregnancy
Proof of Concept Study
Receptors, Fc* / antagonists & inhibitors
Receptors, Fc* / blood
Receptors, Fc* / immunology
Secondary Prevention / methods

Substances

Immunoglobulin G
Isoantigens
Antibodies, Monoclonal
Fc receptor, neonatal
Receptors, Fc
Histocompatibility Antigens Class I
Immunoglobulins, Intravenous